Levetiracetam Tablet, Film Coated
Product Images NDC 0378-5615

13 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0378-5615). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pedatric Patient Dose Calculation (Image 06)

Pedatric Patient Dose Calculation (Image 06)
A formula displayed in text for calculating total daily dose of medication based on patient's weight and daily dose in mg/kg/day divided by concentration, expressed as 100 mg/mL. This instructional text relates to dosing calculations for a drug solution.*
FDA Label Image

Creatinine Clearance Calculation (Image 07)

Creatinine Clearance Calculation (Image 07)
Mathematical formula showing the calculation for creatinine clearance (CLcr) based on age, weight, and serum creatinine levels, including an adjustment factor for female patients.*
FDA Label Image

Creatinine Clearance Bsa Calculation (Image 08)

Creatinine Clearance Bsa Calculation (Image 08)
An instructional equation diagram illustrating the calculation of creatinine clearance normalized to a standard body surface area of 1.73 m². The formula shows creatinine clearance (CLcr) in mL/min/1.73 m² as the product of measured creatinine clearance (CLcr in mL/min) divided by the patient's body surface area (BSA in m²), multiplied by 1.73.*
FDA Label Image

Levetiracetam Structural Formula (Image 05)

Levetiracetam Structural Formula (Image 05)
Chemical structure of levetiracetam, showing a pyrrolidone ring with an ethyl group, an amide group, and a chiral center indicated by wedge bonds.*
FDA Label Image

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 01)

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 01)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam Tablets 1000 mg/day, and Levetiracetam Tablets 3000 mg/day. The y-axis represents the percentage of patients, with the placebo group showing 7.4%, the 1000 mg/day group 37.1%, and the 3000 mg/day group 39.6%. Both Levetiracetam groups show statistically significant differences versus placebo as indicated by an asterisk.*
FDA Label Image

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 09)

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 09)
Bar graph showing the percentage of patients responding to placebo and Levetiracetam tablets at 1000 mg/day and 3000 mg/day doses. The graph indicates a higher percentage of patient response for both Levetiracetam doses compared to placebo, with values approximately 7.4%, 37.1%, and 39.6%, respectively, and notes statistical significance versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 10)

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 10)
A bar graph showing the percentage of patients responding to Levetiracetam tablets at 1000 mg/day and 2000 mg/day doses compared to placebo. The y-axis represents the percentage of patients from 0% to 45%. The graph indicates 6.3% response for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with a note that these results are statistically significant versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 11)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 11)
Bar chart comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day tablet treatment groups. The placebo group shows 14.4% of patients, while the Levetiracetam group shows 39.4% of patients, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 12)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 12)
A bar chart comparing the percentage of patients responding to Levetiracetam tablets versus placebo. The vertical axis shows the percentage of patients, with Levetiracetam tablets at 44.6% and placebo at 19.6%, indicating a statistically significant result versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 13)

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 13)
Bar graph comparing the percentage of patients between placebo and Levetiracetam Tablets groups, showing higher patient percentage for Levetiracetam Tablets (43.1%) versus placebo (19.6%), with a note indicating statistical significance versus placebo.*
FDA Label Image

Levetiracetam Tablets, Usp 500 mg Bottle Label (Image 02)

Levetiracetam Tablets, Usp 500 mg Bottle Label (Image 02)
Levetiracetam 500 mg film-coated tablets, USP, oral dosage form in a 120-count package by Mylan Pharmaceuticals Inc. The label includes storage instructions, a barcode, dosing caution to dispense with medication guide, and states Rx only. The container is described as light-resistant with a child-resistant closure.*
FDA Label Image

Levetiracetam Tablets, Usp 750 mg Bottle Label (Image 03)

Levetiracetam Tablets, Usp 750 mg Bottle Label (Image 03)
Levetiracetam 750 mg film-coated tablets label featuring Mylan Pharmaceuticals Inc. as the manufacturer. The label includes dosage strength prominently, NDC 0378-5617-78, and indicates 120 tablets per container. It shows storage instructions, barcode, and specifies the need for a medication guide with dispensing.*
FDA Label Image

Levetiracetam Tablets, Usp 1000 mg Bottle Label (Image 04)

Levetiracetam Tablets, Usp 1000 mg Bottle Label (Image 04)
Packaging label for Levetiracetam 1000 mg film-coated tablets by Mylan Pharmaceuticals Inc. The label shows the drug name, strength, dosage form, and a tablet image. It indicates 60 tablets per container, includes storage instructions (20° to 25°C), and a pharmacist note to dispense the medication guide. The label also has NDC 0378-5619-91, barcode, and manufacturing details for Mylan Pharmaceuticals in Morgantown, WV, U.S.A., made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.